Position in BIIB
as of Jun 30, 2026
· filed Aug 18, 2026
Position Value
$5,206,397
+$1,213,837 QoQ
Shares Held
24,097
+10.6% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#236
of 1,031 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BIIB Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Rakuten Investment Management, Inc. holds $465,441,591 across 8 Drug Manufacturers - General names. BIIB ranks #8 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
130,079 | $156,020,667 | |
| 2 | JNJ |
Johnson & Johnson
|
393,806 | $100,014,909 | |
| 3 | ABBV |
AbbVie Inc.
|
289,091 | $72,746,859 | |
| 4 | MRK |
Merck & Co., Inc.
|
404,114 | $51,928,649 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
299,116 | $37,790,315 | |
| 6 | PFE |
Pfizer Inc
|
931,567 | $22,432,133 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
334,982 | $19,301,662 | |
| 8 | BIIB |
Biogen Inc.
This page
|
24,097 | $5,206,397 |
All Filings in BIIB
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,206,397 | 24,097 | Shares | Sole | 2026-08-18 | |
| 2026-03-31 | $3,992,560 | 21,778 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $3,395,727 | 19,295 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $27,815,965 | 198,572 | Shares | Sole | 2025-10-30 | |
| 2025-03-31 | $2,560,002 | 18,708 | Shares | Sole | 2025-05-15 | |
| 2024-09-30 | $2,241,953 | 11,566 | Shares | Sole | 2025-05-15 | |
| 2024-06-30 | $2,005,011 | 8,649 | Shares | Sole | 2025-05-15 | |
| 2024-03-31 | $1,159,873 | 5,379 | Shares | Sole | 2025-05-15 | |
| 2023-12-31 | $92,639 | 358 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||